Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

samsung_bioepis

First Enbrel biosimilar launches in UK

February 16, 2016 Manufacturing and Production, Research and Development Enbrel, Samsung Bioepis, eternacept, rheumatoid arthritis

Following its approval by the European Commission in January, Benepali has become the first biosimilar of Pfizer/Amgen’s Enbrel (etanercept) to …
News
cancer_cells_blue

New 10-minute test will diagnose cancer at home

February 15, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Cancer

Scientists have developed a test for cancer that can diagnose the disease at home with the aid of just a …
News
sandoz_good

Sandoz buys rights to Pfizer biosimilar

February 12, 2016 Medical Communications, Research and Development, Sales and Marketing Pfiizer, Sandoz, biosimilars

Sandoz has announced further expansion to its biosimilars programme with the acquisition of the European rights to Pfizer’s Remicade (infliximab) …
News
incyte

Incyte to stop Jakafi pancreatic, colorectal cancer drug trials

February 11, 2016 Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
News
gene

Genomics England enters bioinformatics partnership with Illumina

February 11, 2016 Research and Development Genomics england, Illumia

Genomics England has announced a new partnership with US-based sequencing specialist Illumina to develop a platform and knowledge base that …
News

Alzheimer’s disease market set to double to $10.4 Billion by 2021

February 11, 2016 Research and Development, Sales and Marketing Alzheimer's disease

The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion …
News
sandoz_building

EMA accepts Sandoz Neulasta biosimilar for review

February 11, 2016 Research and Development Amgen, Neulasta, Novartis, Sandoz

Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …
News

NICE publishes new myeloma guidance

February 10, 2016 Medical Communications, Research and Development Farydak, Novartis, multiple myeloma

NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …
News

Novartis says CDF proposals place “unreasonable” risk on pharma

February 10, 2016 Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis

Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …
News
heptares_logo

Heptares announces positive early-stage dementia trial results

February 10, 2016 Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
News

FDA advisory committee recommends approval of Remicade biosimilar

February 10, 2016 Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion

An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …
News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

New breast cancer initiative brings together pharma and Europe’s top researchers

February 9, 2016 Medical Communications, Research and Development Pfizer, breast cancer

The UK charity Breast Cancer Now (BCN) has announced a new initiative seeking to bring together Europe’s top researchers and …
News
fda

FDA set to approve Remicade biosimilar

February 9, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima

An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …
News
nice

NICE rejects cholesterol drug Praluent in draft guidance

February 8, 2016 Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol

NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
News
shire_image_4

FDA to decide on Shire blockbuster hopeful

February 8, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast

The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025